Takeda's No. 1 Position In Japan Threatened By Novartis Inroads
This article was originally published in PharmAsia News
Takeda Pharmaceutical position as the No. 1 drug maker in Japan could face a challenge from Switzerland's Novartis as it moves to expand its Japanese presence
You may also be interested in...
Netherlands' Medicines Evaluation Board says the safety of paracetamol is "not up for debate" after a media investigation reported contamination of the drug with a possible human carcinogen.
There is speculation that it is the end of the road for abicipar pegol but Allergan has declined to say whether this is the case for the product that has been in development for wet AMD.
In the EU, voices calling for a postponement of the IVD Regulation’s 2022 enforcement date are growing louder.